Navigating Share Purchase Agreements versus Asset Purchase Agreements in the MedTech and HealthTech Ecosystems
NA
The structural determination of a transaction in the HealthTech and MedTech sectors, specifically the choice between a Share Purchase Agreement (SPA) and an Asset Purchase Agreement (APA), constitutes the most significant strategic pivot point for investors, founders and legal counsel.
In an industry where valuation is predicated on a complex interplay of regulatory milestones, intellectual property (IP) robustness and high-fidelity patient data, the legal mechanism of transfer serves as the primary arbiter of post-closing operational risk and commercial viability.
This report provides an analysis of these two instruments, detailing their divergent implications for regulatory compliance, data sovereignty, liability allocation and tax efficiency within the specific context of the United Kingdom’s legal and clinical landscape.